PvSTATEM - New tools for the control and elimination of P. vivax malaria
Study sites: Ethiopia, Madagascar
Malaria eradication requires addressing all malaria species, including P. vivax that resists elimination efforts because of its dormant liver forms (“hypnozoites”). These forms cannot be detected with traditional methods, but they can reactivate (“relapse infection”) causing illness and new transmission from people to mosquitoes.
The P. vivax Serological Testing and Treatment in Ethiopia and Madagascar (PvSTATEM) project aims to address this challenge.
We have developed a diagnostic test to identify people likely to carry hypnozoites. These people can be targeted for treatment with primaquine to clear hyponzoites and prevent relapse infection. This combination of a novel diagnostic test and primaquine treatment provides a new intervention for malaria control and elimination.
PvSTATEM aims to identify and treat malaria infected people, before they develop symptoms, to prevent transmission of P. vivax malaria. The consortium plans to assess the efficacy, safety, and acceptability of this intervention (objectives 1 & 2), as well as to develop digital approaches for better implementation (objective 3) and machine learning tools for malaria surveillance at the level of entire populations (objective 4). Find out more.
The core principle & objectives
vivax malaria
5-year project
9 partners
9 countries
EU & UKRI funding
We are specifically addressing Sustainable Development Goals related to good health & well-being and to gender equality.
Partners
